| Literature DB >> 34845719 |
Konrad Wagstyl1, Kirstie Whitaker2, Armin Raznahan3, Jakob Seidlitz4,5, Petra E Vértes6, Stephen Foldes7, Zachary Humphreys7, Wenhan Hu8, Jiajie Mo8, Marcus Likeman9, Shirin Davies10,11, Matteo Lenge12, Nathan T Cohen13, Yingying Tang14,15, Shan Wang15,16, Mathilde Ripart17, Aswin Chari17,18, Martin Tisdall17,18, Nuria Bargallo19,20, Estefanía Conde-Blanco19,20, Jose Carlos Pariente20, Saül Pascual-Diaz20, Ignacio Delgado-Martínez21, Carmen Pérez-Enríquez21, Ilaria Lagorio22, Eugenio Abela23, Nandini Mullatti24, Jonathan O'Muircheartaigh24, Katy Vecchiato24, Yawu Liu25, Maria Caligiuri26, Ben Sinclair27,28, Lucy Vivash27,28, Anna Willard27,28, Jothy Kandasamy29, Ailsa McLellan29, Drahoslav Sokol29, Mira Semmelroch30, Ane Kloster31, Giske Opheim31, Clarissa Yasuda32, Kai Zhang8, Khalid Hamandi10,11, Carmen Barba12, Renzo Guerrini12, William Davis Gaillard13, Xiaozhen You13, Irene Wang15, Sofía González-Ortiz21, Mariasavina Severino22, Pasquale Striano22, Domenico Tortora22, Reetta Kalviainen25,33, Antonio Gambardella26, Angelo Labate26, Patricia Desmond34, Elaine Lui34, Terry O'Brien27,28, Jay Shetty29, Graeme Jackson30, John S Duncan35, Gavin P Winston35,36, Lars Pinborg31, Fernando Cendes32, Judith Helen Cross17,18, Torsten Baldeweg17,18, Sophie Adler17,18.
Abstract
OBJECTIVE: Drug-resistant focal epilepsy is often caused by focal cortical dysplasias (FCDs). The distribution of these lesions across the cerebral cortex and the impact of lesion location on clinical presentation and surgical outcome are largely unknown. We created a neuroimaging cohort of patients with individually mapped FCDs to determine factors associated with lesion location and predictors of postsurgical outcome.Entities:
Keywords: MRI; drug-resistant epilepsy; focal cortical dysplasia; lesions; neurosurgery
Mesh:
Year: 2021 PMID: 34845719 PMCID: PMC8916105 DOI: 10.1111/epi.17130
Source DB: PubMed Journal: Epilepsia ISSN: 0013-9580 Impact factor: 5.864
FIGURE 4Interrelationships between features. (A) Pairwise comparison of demographic and clinical features. Significant relationships after correction for multiple comparisons are shown in yellow. (B) Statistical test used for each pairwise comparison. (C) Distributions of age at epilepsy onset, age at magnetic resonance imaging (MRI) scan, and duration of epilepsy. (D) Duration of epilepsy is significantly associated with seizure freedom (t = −3.0, p < .001). Patients with longer durations of epilepsy are less likely to be seizure‐free. (E) Age at epilepsy onset, lesion size (as a percentage of the total hemisphere size), and seizure freedom are significantly associated. Larger lesions are associated with younger age at epilepsy onset (r = −0.24, p < .001) and are more likely to be operated on (t = 3.69, p < .001). Similarly, patients with a younger age at epilepsy onset are more likely to be operated on (t = −3.76, p < .001). Anova, analysis of variance; Na, not applicable
Demographics table
| Characteristic | FCD patients, |
|---|---|
| Age at scan, median years (IQR) | 19.0 (11.0–31.3) |
| Sex, female:male | 281:298 |
| Age at onset, median years (IQR) | 6.0 (2.5–12.0) |
| Ever reported MRI‐negative | 188/580 (32%) |
| Duration of epilepsy, median years (IQR) | 10.4 (4.9–19.0) |
| Surgery performed | 423/580 (73%) |
| Histopathology available | 380/580 (66%) |
| Outcome available | 275/580 (47%) |
| Follow‐up time, median years (IQR) | 2.0 (1.3–3.4) |
Abbreviations: FCD, focal cortical dysplasia; IQR, interquartile range; MRI, magnetic resonance imaging.
Histopathology and surgical outcome
| FCD subtype | Histopathology, | Seizure‐free, | Ever reported MRI‐negative, |
|---|---|---|---|
| All | 380 (100%) | 165/252 (65%) | 135/380 (36%) |
| FCD Type I | 42 (11%) | 17/31 (55%) | 17/42 (40%) |
| FCD Type IIA | 118 (31%) | 58/84 (69%) | 55/118 (47%) |
| FCD Type IIB | 199 (52%) | 80/121 (66%) | 55/199 (28%) |
| FCD Type III | 21 (6%) | 10/16 (62%) | 8/21 (38%) |
Histopathology = histopathological diagnosis; Histopathology % = percentage of patients with particular histopathological diagnosis out of the total number of patients with histopathology; Seizure‐free = number of patients with a particular histopathological diagnosis who were seizure‐free out of the total number of patients with FCD subtype and outcome data available; n = number of patients.
Abbreviations: FCD, focal cortical dysplasia; MRI, magnetic resonance imaging.
FIGURE 1Distribution of focal cortical dysplasia (FCD) lesions across the cerebral cortex. (A) All FCD lesion masks mapped to the left hemisphere of the template cortical surface. The distribution of FCDs across the cerebral cortex is nonuniform, with higher concentrations in the superior frontal sulcus, frontal pole, temporal pole, and superior temporal gyrus. (B) Three‐dimensional lesion likelihood atlas. Aggregated surface‐based lesion map values were normalized to between 0 and 1 and mapped back to the template magnetic resonance imaging volume. (C) Sample size required for consistent FCD lesion map. Rank correlation (y axis) was calculated by comparing the lesion map from a smaller cohort to a larger withheld cohort (n = 250). r increased with sample size. Predictive learning curve (red line) estimated that a stable map of lesion distribution requires a sample size of n = 400. (D) Distribution of FCD lesions according to histopathological subtype. (E) Distributions of lesions across cortical lobes within each FCD histopathological subtype. The width of bars indicates the relative numbers of patients. Temporal lobe lesions made up larger proportions of FCD Types I and III, whereas frontal lobe lesions were more likely to be FCD Types IIA and IIB
FIGURE 2Presurgical factors associated with lesion location. Surface‐based maps show distribution of demographic variables according to lesion location. The color at each vertex represents the average variable value for patients with overlapping lesions. Vertices where the presence of a focal lesion was significantly associated with that variable are delineated in red. Factors significantly (p < .01) associated with lesion location were (Ai) age at epilepsy onset, (Bi) duration of epilepsy, and (Bii) lesion size. (Aiii) Correlation between the sensorimotor‐association axis of cortical organization (Aii) and the age at epilepsy onset (Ai) maps in comparison to spatially permuted maps. Lesions in primary areas were associated with a younger age at onset, whereas association areas had older ages of onset (r = 0.39, p < .01). (Biii) Correlation between the duration of epilepsy (Bi) and lesion size (Bii) maps in comparison to spatially permuted maps. Mean duration was significantly negatively correlated with the size of epilepsy lesion, where cortical areas with smaller lesions, for example, precentral and frontal areas, were associated with a longer duration of epilepsy, whereas areas with larger lesions, for example, occipital cortex, had shorter durations of epilepsy (r = −0.42, p < .05)
FIGURE 3Effect of lesion location, duration of epilepsy, and histopathological subtype on seizure freedom. (Ai) Percentage of patients seizure‐free (%) according to lesion location across the cerebral cortex. Visual, motor, and premotor areas had a low percentage of seizure‐free patients (30%–40%). (Aii) Mask of eloquent cortex. (B) Impact of overlap of lesion with eloquent cortex and magnetic resonance imaging scanner field strength on likelihood of seizure freedom. (C) Impact of duration and histopathology on predicted percentage likelihood of seizure freedom. FCD, focal cortical dysplasia; NA, not available